E.M. Noordijk - Concepedia

Author

E.M. Noordijk

Also Known As

E M Noordijk, E NOORDIJK, E Noordijk, E. M. Noordijk, E.M Noordijk, E.M. Noordijk, EM Noordijk, HC Kluin-Nelemans, Noordijk

Publications

3.9K

Citations

H-Index

Concepts

All Affiliations

Leiden University Medical Center Leiden University Netherlands Comprehensive Cancer Organisation Institut Gustave Roussy Radboud University Nijmegen

About

E.M. Noordijk is an author at Leiden University Medical Center specializing in medicine, oncology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	19	1.5K
2	Health Sciences	4	4	457
3	Public Health	2	2	30
4	Engineering	1	1	13
5	Social Sciences	1	1	19

E.M. Noordijk

Publications

3.8K

Citations

H-Index

Page 1

	Year	Citations
Roles of Radiation Dose, Chemotherapy, and Hormonal Factors in Breast Cancer Following Hodgkin's Disease Flora E. van Leeuwen, Willem J. Klokman, Marilyn Stovall, JNCI Journal of the National Cancer Institute	2003	393
Primary extranodal non-Hodgkin’s lymphoma (NHL): the impact of alternative definitions tested in the Comprehensive Cancer Centre West population-based NHL registry Augustinus D. G. Krol, Saskia le Cessie, Simone Snijder, Annals of Oncology Lymphoid NeoplasiaOncologyCancer EpidemiologyAlternative DefinitionsPathology	2002	263
Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin's disease. The EORTC Lymphoma Group controlled clinical trials: 1964-1987 M Tubiana, M. Henry‐Amar, Patrice Carde, Blood	1989	261
Radiotherapy does not compensate for positive resection margins in rectal cancer patients: report of a multicenter randomized trial Corrie A.M. Marijnen, Irıs D. Nagtegaal, Ellen Kapiteijn, International Journal of Radiation OncologyBiologyPhysics Rectal Cancer PatientsSurgical OncologyRadiation TherapyMedicineCancer Recurrence	2003	258
Comparative analysis of risk factors for pathological fracture with femoral metastases Yvette M. van der Linden, P. D. S. Dijkstra, Herman M. Kroon, Journal of Bone and Joint Surgery - British Volume Bone DiseaseSkeletal TraumaSpinal FractureScoring SystemOsteoarthritis	2004	227
CHOP is the standard regimen in patients > or = 70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group. Umberto Tirelli, D. Errante, M. van Glabbeke, Journal of Clinical Oncology	1998	219
Mantle-cell lymphoma: a population-based clinical study. Gerjo A. Velders, Hanneke C. Kluin‐Nelemans, Carla J. de Boer, Journal of Clinical Oncology	1996	188
Primary non-Hodgkin’s lymphoma of bone: a clinicopathological investigation of 60 cases FH Heyning, MHH Kramer, Jos Hermans, Leukemia Lymphoid NeoplasiaOrthopaedic SurgeryClinicopathological Investigation	1999	175
Clinical stages I and II Hodgkin's disease: a specifically tailored therapy according to prognostic factors. Patrice Carde, J M Burgers, M. Henry‐Amar, Journal of Clinical Oncology Prognostic FactorsSurgical OncologyImmunodeficienciesCancer ManagementPathology	1988	168
Efficacy of four different regimens in 64 mantle-cell lymphoma cases: clinicopathologic comparison with 498 other non-Hodgkin's lymphoma subtypes. European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group. Ivana Teodorović, Stefania Pittaluga, Hanneke C. Kluin‐Nelemans, Journal of Clinical Oncology	1995	156

Page 1